vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and Sachem Capital Corp. (SACH). Click either name above to swap in a different company.
Sachem Capital Corp. is the larger business by last-quarter revenue ($12.0M vs $9.5M, roughly 1.3× Cellectis S.A.). Sachem Capital Corp. runs the higher net margin — 8.3% vs -265.9%, a 274.2% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -18.8%).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
CLLS vs SACH — Head-to-Head
Income Statement — Q2 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $12.0M |
| Net Profit | $-25.3M | $997.0K |
| Gross Margin | — | — |
| Operating Margin | -181.1% | -3.1% |
| Net Margin | -265.9% | 8.3% |
| Revenue YoY | 375.0% | -18.8% |
| Net Profit YoY | -51.9% | 119.7% |
| EPS (diluted) | $-0.28 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $12.0M | ||
| Q2 25 | — | $10.8M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $10.8M | ||
| Q3 24 | — | $14.8M | ||
| Q2 24 | $9.5M | $15.1M | ||
| Q1 24 | — | $16.8M | ||
| Q4 23 | — | $16.0M |
| Q3 25 | — | $997.0K | ||
| Q2 25 | — | $1.9M | ||
| Q1 25 | — | $904.0K | ||
| Q4 24 | — | $-36.1M | ||
| Q3 24 | — | $-5.1M | ||
| Q2 24 | $-25.3M | $-3.1M | ||
| Q1 24 | — | $4.7M | ||
| Q4 23 | — | $-1.1M |
| Q3 25 | — | -3.1% | ||
| Q2 25 | — | 9.9% | ||
| Q1 25 | — | 9.0% | ||
| Q4 24 | — | -131.1% | ||
| Q3 24 | — | -32.6% | ||
| Q2 24 | -181.1% | -20.6% | ||
| Q1 24 | — | 25.4% | ||
| Q4 23 | — | — |
| Q3 25 | — | 8.3% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 7.9% | ||
| Q4 24 | — | -335.6% | ||
| Q3 24 | — | -34.2% | ||
| Q2 24 | -265.9% | -20.2% | ||
| Q1 24 | — | 27.8% | ||
| Q4 23 | — | -6.9% |
| Q3 25 | — | $0.00 | ||
| Q2 25 | — | $0.02 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | — | $-0.13 | ||
| Q2 24 | $-0.28 | $-0.09 | ||
| Q1 24 | — | $0.08 | ||
| Q4 23 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $12.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $148.6M | $175.6M |
| Total Assets | $407.1M | $484.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $12.6M | ||
| Q2 25 | — | $23.5M | ||
| Q1 25 | — | $25.8M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | — | $7.4M | ||
| Q2 24 | $149.0M | $12.4M | ||
| Q1 24 | — | $56.8M | ||
| Q4 23 | — | $50.4M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $230.2M | ||
| Q4 24 | — | $230.2M | ||
| Q3 24 | — | $264.7M | ||
| Q2 24 | — | $264.7M | ||
| Q1 24 | — | $288.4M | ||
| Q4 23 | — | $288.4M |
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $179.3M | ||
| Q4 24 | — | $181.7M | ||
| Q3 24 | — | $220.6M | ||
| Q2 24 | $148.6M | $230.2M | ||
| Q1 24 | — | $237.4M | ||
| Q4 23 | — | $230.1M |
| Q3 25 | — | $484.4M | ||
| Q2 25 | — | $501.8M | ||
| Q1 25 | — | $491.4M | ||
| Q4 24 | — | $492.0M | ||
| Q3 24 | — | $555.5M | ||
| Q2 24 | $407.1M | $586.3M | ||
| Q1 24 | — | $626.5M | ||
| Q4 23 | — | $620.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 1.21× | ||
| Q4 23 | — | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $4.9M |
| Free Cash FlowOCF − Capex | $27.6M | — |
| FCF MarginFCF / Revenue | 290.5% | — |
| Capex IntensityCapex / Revenue | 13.2% | — |
| Cash ConversionOCF / Net Profit | — | 4.95× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $4.9M | ||
| Q2 25 | — | $501.0K | ||
| Q1 25 | — | $191.0K | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | $28.9M | $7.0M | ||
| Q1 24 | — | $4.2M | ||
| Q4 23 | — | $2.9M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | — | 4.95× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.90× | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
